The 36-month beta value for IGMS is also noteworthy at 0.18. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for IGMS is 20.77M, and at present, short sellers hold a 27.84% of that float. The average trading volume of IGMS on September 11, 2024 was 280.19K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IGMS) stock’s latest price update
IGM Biosciences Inc (NASDAQ: IGMS)’s stock price has soared by 9.74 in relation to previous closing price of 10.27. Nevertheless, the company has seen a gain of 14.30% in its stock price over the last five trading days. globenewswire.com reported 2024-09-10 that MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
IGMS’s Market Performance
IGMS’s stock has risen by 14.30% in the past week, with a monthly rise of 30.74% and a quarterly rise of 45.98%. The volatility ratio for the week is 10.90% while the volatility levels for the last 30 days are 9.71% for IGM Biosciences Inc The simple moving average for the past 20 days is 14.08% for IGMS’s stock, with a 18.44% simple moving average for the past 200 days.
Analysts’ Opinion of IGMS
Many brokerage firms have already submitted their reports for IGMS stocks, with RBC Capital Mkts repeating the rating for IGMS by listing it as a “Outperform.” The predicted price for IGMS in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on February 09, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see IGMS reach a price target of $8. The rating they have provided for IGMS stocks is “Neutral” according to the report published on December 15th, 2023.
H.C. Wainwright gave a rating of “Neutral” to IGMS, setting the target price at $7 in the report published on December 07th of the previous year.
IGMS Trading at 17.64% from the 50-Day Moving Average
After a stumble in the market that brought IGMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.33% of loss for the given period.
Volatility was left at 9.71%, however, over the last 30 days, the volatility rate increased by 10.90%, as shares surge +27.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +64.05% upper at present.
During the last 5 trading sessions, IGMS rose by +14.30%, which changed the moving average for the period of 200-days by +97.72% in comparison to the 20-day moving average, which settled at $10.00. In addition, IGM Biosciences Inc saw 35.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGMS starting from Hambleton Julie, who sale 15,132 shares at the price of $14.00 back on Jul 25 ’24. After this action, Hambleton Julie now owns 2,000 shares of IGM Biosciences Inc, valued at $211,848 using the latest closing price.
Weber Steven, the PRINCIPAL ACCOUNTING OFFICER of IGM Biosciences Inc, sale 495 shares at $7.58 during a trade that took place back on Jun 14 ’24, which means that Weber Steven is holding 26,012 shares at $3,750 based on the most recent closing price.
Stock Fundamentals for IGMS
Current profitability levels for the company are sitting at:
- -81.45 for the present operating margin
- -2.05 for the gross margin
The net margin for IGM Biosciences Inc stands at -75.71. The total capital return value is set at -0.79. Equity return is now at value -115.71, with -53.94 for asset returns.
Based on IGM Biosciences Inc (IGMS), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.26. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is -59.6.
Currently, EBITDA for the company is -255.18 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 220.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.06.
Conclusion
In summary, IGM Biosciences Inc (IGMS) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
